Sagimet Biosciences Inc. SGMT
9.24
0.13
1.43%
as of 25 Sep
- Market cap
- $561.1M
- P/E
- 0.0×
Follow SGMT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
44.31 | 19.74 | 22.18 | 12.76 | |
Current Ratio |
45.02 | 20.34 | 22.82 | 13.06 | |
Net Debt/EBITDA |
15.16 | 8.82 | 10.81 | 8.18 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.81 | 1.24 | 0.79 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.26) | (0.37) | (0.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.26) | (0.37) | (0.31) | |
Cash per Share |
4.52 | 3.21 | 3.50 | 3.59 | |
Shareholders Equity per Share |
4.82 | 3.15 | 3.44 | 3.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.82 | 3.15 | 3.44 | 3.67 | |
Free Cash Flow |
(11.10) | (8.61) | (11.83) | (10.18) | |
Working Capital |
238.57 | 102.42 | 111.30 | 110.33 | |
Net Current Asset Value |
236.71 | 102.42 | 111.30 | 110.33 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
1.53 | 2.76 | 1.37 | 2.70 | |
Average Assets |
200.42 | 126.96 | 138.37 | 151.59 | |
Average Common Equity |
193.16 | 120.73 | 133.59 | 144.97 |
Columns are period end dates